Low serum omentin levels in the elderly population with Type 2 diabetes and polyneuropathy. Issue 11 (11th June 2015)

• Record Type: Journal Article
• Authors: Herder, C.; Bongaerts, B. W. C.; Ouwens, D. M.; Rathmann, W.; Heier, M.; Carstensen‐Kirberg, M.; Koenig, W.; Thorand, B.; Roden, M.; Meisinger, C.; Ziegler, D.; for the KORA Study Group
• Is Part Of: Diabetic medicine. Volume 32:Issue 11(2015:Nov.)
• Page Start: 1479
• Page End: 1483
• Publication Date: 2015-06-11
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.12761
• Languages: English
• ISSNs: 0742-3071

Abstract

<abstract abstract-type="main" id="dme12761-abs-0001"> <title>Abstract</title> <sec id="dme12761-sec-0001" sec-type="section"> <title>Aims</title> <p>To investigate the hypothesis that high serum levels of omentin, an adipokine with anti‐inflammatory, insulin‐sensitizing and cardioprotective properties, may be related to a lower risk of diabetic sensorimotor polyneuropathy.</p> </sec> <sec id="dme12761-sec-0002" sec-type="section"> <title>Methods</title> <p>The association between serum omentin level and polyneuropathy was estimated in people aged 61–82 years with Type 2 diabetes (47 with and 168 without polyneuropathy) from the population‐based KORA F4 study. The presence of clinical diabetic sensorimotor polyneuropathy was defined as bilateral impairment of foot vibration perception and/or foot pressure sensation. Omentin levels were determined by enzyme‐linked immunosorbent assay.</p> </sec> <sec id="dme12761-sec-0003" sec-type="section"> <title>Results</title> <p>Serum omentin level was inversely associated with polyneuropathy after adjustment for age, sex, height, waist circumference, hypertension, total cholesterol, smoking, alcohol intake and physical activity [odds ratio 0.45 (95% CI 0.21–0.98); <italic>P </italic>=<italic> </italic>0.043]. Although omentin was positively correlated with adiponectin (r = 0.55, <italic>P </italic>< 0.0001) and inversely with tumour necrosis factor‐α (<italic>r </italic>=<italic> </italic>‐0.30, <italic>P </italic>=<italic> </italic>0.019), additional adjustment for adiponectin and tumour necrosis factor‐α had little impact on the association.</p> </sec> <sec id="dme12761-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Serum levels of omentin are reduced in people with Type 2 diabetes and diabetic sensorimotor polyneuropathy, independently of established risk factors of polyneuropathy. This association is only partially explained by biomarkers of subclinical inflammation.</p> </sec> </abstract>